Scientometrics
Copyright ©The Author(s) 2022. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Clin Cases. Jan 14, 2022; 10(2): 594-606
Published online Jan 14, 2022. doi: 10.12998/wjcc.v10.i2.594
Biologic therapy for Crohn’s disease over the last 3 decades
Ji-Liang Shen, Zheng Zhou, Jia-Sheng Cao, Bin Zhang, Jia-Hao Hu, Jia-Ying Li, Xiao-Ming Liu, Sarun Juengpanich, Ming-Song Li, Xu Feng
Ji-Liang Shen, Jia-Sheng Cao, Bin Zhang, Jia-Hao Hu, Sarun Juengpanich, Xu Feng, Department of General Surgery, Sir Run-Run Shaw Hospital, Zhejiang University School of Medicine, Hangzhou 310016, Zhejiang Province, China
Zheng Zhou, Jia-Ying Li, Xiao-Ming Liu, Ming-Song Li, Department of Gastroenterology, Nan Fang Hospital, Southern Medical University, Guangzhou 510515, Guangdong Province, China
Ming-Song Li, Department of Gastroenterology, Third Affiliated Hospital of Guangzhou Medical University, Guangzhou 510000, Guangdong Province, China
Author contributions: Shen JL and Feng X designed the study and collected the data; Shen JL, Zhou Z, and Cao JS analyzed and interpreted the data; Zhou Z, Cao JS, Zhang B, Hu JH, Li JY, Liu XM, and Li MS wrote the manuscript; Juengpanich S and Feng X revised the manuscript; all authors made final approval of the version of the manuscript.
Supported by the National Natural Science Foundation of China, No. 81800540; and Key Research and Development Project of Zhejiang Province, No. 2018C03083.
Conflict-of-interest statement: The authors declare that they have no conflict of interest.
PRISMA 2009 Checklist statement: The authors have read the PRISMA 2009 Checklist, and the manuscript was prepared and revised according to the PRISMA 2009 Checklist.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Xu Feng, MD, PhD, Surgeon, Department of General Surgery, Sir Run-Run Shaw Hospital, Zhejiang University School of Medicine, No. 3 East Qingchun Road, Hangzhou 310016, Zhejiang Province, China. phoneshe@zju.edu.cn
Received: August 8, 2021
Peer-review started: August 8, 2021
First decision: October 11, 2021
Revised: October 19, 2021
Accepted: December 7, 2021
Article in press: December 7, 2021
Published online: January 14, 2022
Processing time: 156 Days and 11.8 Hours
Abstract
BACKGROUND

Despite the overload of publications on Crohn’s disease (CD), no comprehensive analysis of biologic therapy for CD has been reported.

AIM

To determine knowledge gaps and identify areas of interest of biologic therapy for CD.

METHODS

The top 100 highest-cited original articles were identified from January 1991 to December 2020 in the Clarivate Analytics Web of Science Core Collection database. We conducted a bibliometric analysis of biologic therapy for CD based on total citations, summarized the bibliographic information of the articles related to CD biologic therapy, and explored the research hotspots.

RESULTS

The top 100 highest-cited original articles were identified with total citations ranging from 307 to 2978. The 2000s (Period II, n = 66) yielded the most influential original articles and saw the most dramatic growth. Among the top 10 countries, including 8 European countries and 2 North American countries, the United States (n = 37) and Belgium (n = 20) contributed the most publications. Among the top 10 institutions, the University Hospital Gasthuisberg in Belgium (n = 23), the University of Chicago in the United States (n = 20), and the Mayo Clinic in the United States (n = 17) published the most papers. Regarding authors, Rutgeerts P in Belgium (n = 32), Sandborn WJ in the United States (n = 23), and Feagan BG in Canada (n = 18) published the highest number of studies. The cooperation relationships between the United States and Europe were most frequent. Gastroenterology (impact factor = 22.682) published the most articles on biologic therapy for CD (n = 32) with 17654 total citations. Anti-tumor necrosis factor biologics and monoclonal antibodies were the most studied topics.

CONCLUSION

The bibliometric analysis emphasized the key contributions to the development of the specialized field. These data would provide useful research insights into biologic therapy for CD for clinicians and researchers.

Keywords: Biologic therapy; Crohn’s disease; Bibliometric analysis; Most influential; Insight

Core Tip: We conducted a bibliometric analysis from the top 100 highest-cited original articles to determine knowledge gaps and identify areas of interest of biologic therapy for Crohn’s disease (CD). The 2000s yielded the most influential original articles and saw the most dramatic growth. The United States and Europe contributed the most publications, and the cooperation relationships between them were most frequent. Gastroenterology published the most articles on biologic therapy for CD. Anti-tumor necrosis factor (TNF) biologics and monoclonal antibodies were the most studied topics. These data would provide useful research insights into biologic therapy for CD for clinicians and researchers.